Active, not recruitingPHASE1, PHASE2NCT05845749
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
Studying Mucopolysaccharidosis type 4A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Ellen B Fung, PhDUniversity of California, San Francisco
- Intervention
- Vosoritide Injection [Voxzogo](drug)
- Enrollment
- 6 enrolled
- Eligibility
- 5-10 years · All sexes
- Timeline
- 2023 – 2029
Study locations (1)
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05845749 on ClinicalTrials.gov